Suzhou Zhonglian Chemical Pharmaceutical Co., Ltd. has been rooted in the high-tech zone of Wuhu for nearly ten years. Today, the company not only leads the industry in the field of cephalosporin bulk drugs, but also extends the industrial chain to the formulation field through transformation and upgrading, becoming a domestic high-end small cephalosporin. A leader in the pharmaceutical industry.

The research and development center of Zhonglian Pharmaceutical was established in the Science and Technology Park of Wuhu High-tech Zone. Nowadays, the APIs for the production of 18 cephalosporins have passed the new GMP certification, and cefaclor has a market share of 70% in the domestic market, ranking first in the industry. Such a high market share benefits from the dual advantages of technology and cost, but for Zhonglian Pharmaceutical, the most fundamental advantage is the talent advantage. "Technical advantages are very important. A company must have its competitiveness. The core competitiveness lies in your technology and the technology of your talent reserve. This is very important. Today, Zhonglian's senior talent team There are more than 30 people, including 4 senior engineers and 4 graduate students. In addition, they also cooperate with universities such as Jiangsu University of Pharmacy and Shanghai Jiaotong University, and plan to establish academician workstations and national “Thousand Talents Program” workstations. General Manager Liu of Chemical Pharmaceutical Co., Ltd. said.

In recent years, the company's performance has increased year by year, and the benefits have been remarkable. However, the company's management clearly recognizes that APIs are still relatively low-end products in the pharmaceutical industry. Enterprises must further develop, only upgrade and transform, and do a bigger job. Continue to develop. This year, China United invested 200 million yuan to build a new factory. On the one hand, it hopes to make more exquisite production of raw materials, and go abroad to sell to India, South America and other countries. On the other hand, it strives to make new breakthroughs in formulation and achieve leapfrog development.